Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (2016 - 2025)

UroGen Pharma's Shares Outstanding history spans 10 years, with the latest figure at $48.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 14.57% year-over-year to $48.4 million; the TTM value through Dec 2025 reached $48.4 million, up 14.57%, while the annual FY2025 figure was $48.4 million, 14.57% up from the prior year.
  • Shares Outstanding reached $48.4 million in Q4 2025 per URGN's latest filing, up from $46.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $48.4 million in Q4 2025 to a low of $22.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $32.6 million, with a median of $28.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 1.33% in 2021, then skyrocketed 75.2% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $22.5 million in 2021, then grew by 2.97% to $23.1 million in 2022, then skyrocketed by 40.47% to $32.5 million in 2023, then grew by 29.89% to $42.2 million in 2024, then rose by 14.57% to $48.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Shares Outstanding are $48.4 million (Q4 2025), $46.8 million (Q3 2025), and $46.2 million (Q2 2025).